8.07
-0.02(-0.25%)
Currency In USD
| Previous Close | 8.09 |
| Open | 8.1 |
| Day High | 8.24 |
| Day Low | 8 |
| 52-Week High | 9.48 |
| 52-Week Low | 6.5 |
| Volume | 1.37M |
| Average Volume | 1.71M |
| Market Cap | 2.53B |
| PE | -201.75 |
| EPS | -0.04 |
| Moving Average 50 Days | 7.87 |
| Moving Average 200 Days | 8.09 |
| Change | -0.02 |
If you invested $1000 in Amneal Pharmaceuticals, Inc. (AMRX) since IPO date, it would be worth $537.64 as of July 31, 2025 at a share price of $8.07. Whereas If you bought $1000 worth of Amneal Pharmaceuticals, Inc. (AMRX) shares 5 years ago, it would be worth $1,863.74 as of July 31, 2025 at a share price of $8.07.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Amneal Announces Proposed Refinancing of Existing Credit Agreement, including Private Offering of Senior Secured Notes Due 2032
GlobeNewswire Inc.
Jul 21, 2025 11:39 AM GMT
BRIDGEWATER, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal”) (Nasdaq: AMRX) announced that its subsidiary, Amneal Pharmaceuticals LLC (the “Issuer”), is seeking to borrow $1.800 billion aggregate principal amount of
Amneal to Report Second Quarter 2025 Results on August 5, 2025
GlobeNewswire Inc.
Jul 09, 2025 12:00 PM GMT
BRIDGEWATER, N.J., July 09, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today announced that the Company will release its second quarter 2025 financial result
Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences
GlobeNewswire Inc.
Jun 25, 2025 12:00 PM GMT
Amneal holds exclusive U.S. commercialization rights; BLA filing expected in Q4 2025 Poised to be among the first wave of biosimilars in the $3.9 billion U.S. omalizumab market and an important growth driver for Amneal BRIDGEWATER, N.J., June 25, 20